A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

[1]  G. Batist,et al.  Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors , 2019, Clinical Trials.

[2]  J. Leonard,et al.  Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Bhatt,et al.  A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. , 2017, European journal of medicinal chemistry.

[4]  N. McMillan,et al.  Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data. , 2017, Critical reviews in oncology/hematology.

[5]  C. Prigent,et al.  Aurora A Kinase Is a Priority Pharmaceutical Target for the Treatment of Cancers. , 2017, Trends in pharmacological sciences.

[6]  Freddy Radtke,et al.  Corneal epithelial stem cells and their niche at a glance , 2017, Journal of Cell Science.

[7]  Junnian Zheng,et al.  Aurora kinases: novel therapy targets in cancers , 2017, Oncotarget.

[8]  Byung-Hyun Park,et al.  Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases , 2016, Oncotarget.

[9]  N. Fujita,et al.  433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase , 2014 .

[10]  Kimihiro Ito,et al.  398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer models , 2014 .

[11]  D. Zheleva,et al.  Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.

[12]  Paul A. Rejto,et al.  An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 , 2012, Molecular Cancer Therapeutics.

[13]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[14]  A. Cervantes,et al.  Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  T. Magnuson,et al.  Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development , 2008, Molecular and Cellular Biology.

[16]  Jie Xu,et al.  Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. , 2008, Carcinogenesis.

[17]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[18]  T. Manabe,et al.  Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC) , 2007, Annals of Surgical Oncology.

[19]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[20]  S. Sen,et al.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.

[21]  David B Jackson,et al.  Relationships of clinical response to relevant molecular signal during Phase I testing of Aurora Kinase A inhibitor: Retrospective assessment , 2015 .

[22]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[23]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.